Literature DB >> 11300455

Effects of verapamil and lidocaine on two components of the re-entry circuit of verapamil-senstitive idiopathic left ventricular tachycardia.

T Tsuchiya1, K Okumura, T Honda, A Iwasa, K Ashikaga.   

Abstract

OBJECTIVES: We characterized pharmacologically the slow conduction zone of verapamil-sensitive idiopathic left ventricular tachycardia (ILVT) with regard to the late diastolic potential (LDP).
BACKGROUND: We showed that the slow conduction zone of ILVT could be divided into two components by LDP; that is, the distal component with a tachycardia-dependent conduction delay property and the proximal one without it.
METHODS: Electrophysiologic studies were performed in eight consecutive patients. The LDP was recorded during left ventricular (LV) mapping during ILVT. Entrainment was performed from the right ventricular outflow tract while recording LDP. The effects of lidocaine (1 mg/kg body weight) and verapamil (0.5 or 1.0 mg) were examined during entrainment.
RESULTS: The LDPs preceding the Purkinje potential (PP) were serially recorded from the upper third to the middle of the LV septum along the narrow longitudinal line. The ventricular tachycardia (VT) cycle length increased after lidocaine (p < 0.05), and further after verapamil (p < 0.05). The increments in the VT cycle length after administration of the drugs strongly correlated with those in LDP-PP (r > 0.9 for both drugs). The interval from the ventricular potential to LDP was unchanged after administration of the drugs. In one patient, verapamil terminated VT by local conduction block between LDP and PP. The LDP-PP measured during entrainment increased after lidocaine, and further after verapamil, whereas the interval from the stimulus to LDP remained unchanged.
CONCLUSIONS: The component distal to LDP is mainly calcium channel-dependent and partly depressed sodium channel-dependent. The proximal component is considered to be sodium channel-dependent (normal).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300455     DOI: 10.1016/s0735-1097(01)01117-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Optimal ablation strategies for different types of ventricular tachycardias.

Authors:  Takumi Yamada; G Neal Kay
Journal:  Nat Rev Cardiol       Date:  2012-05-29       Impact factor: 32.419

Review 2.  Ventricular arrhythmias and the His-Purkinje system.

Authors:  Michel Haissaguerre; Edward Vigmond; Bruno Stuyvers; Meleze Hocini; Olivier Bernus
Journal:  Nat Rev Cardiol       Date:  2016-01-04       Impact factor: 32.419

Review 3.  Ventricular tachycardia in structurally normal hearts.

Authors:  T Scott Wall; Roger A Freedman
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

4.  Electroanatomical characteristics of idiopathic left ventricular tachycardia and optimal ablation target during sinus rhythm: significance of preferential conduction through Purkinje fibers.

Authors:  Junbeom Park; Young-Hoon Kim; Chun Hwang; Hui-Nam Pak
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

5.  Ventricular tachycardia in the absence of structural heart disease.

Authors:  Komandoor Srivathsan; Steven J Lester; Christopher P Appleton; Luis R P Scott; Thomas M Munger
Journal:  Indian Pacing Electrophysiol J       Date:  2005-04-01

6.  Role of the His bundle in verapamil-sensitive idiopathic left ventricular tachycardia.

Authors:  Akira Fujiki; Ryozo Yoshioka; Masao Sakabe; Eriko Kikuchi
Journal:  HeartRhythm Case Rep       Date:  2015-03-27

7.  Idiopathic Fascicular Left Ventricular Tachycardia.

Authors:  Yaser Alahmad; Nidal Ahmad Asaad; Salaheddin Omran Arafa; Shahul Hameed Ahmad Khan; Alsayed Mahmoud
Journal:  Heart Views       Date:  2017 Jul-Sep

Review 8.  Electrocardiographic characteristics of idiopathic ventricular arrhythmias based on anatomy.

Authors:  Yulong Xiong; Hongling Zhu
Journal:  Ann Noninvasive Electrocardiol       Date:  2020-06-27       Impact factor: 1.468

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.